These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 36165836)

  • 1. Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy.
    Yuan CS; Teng Z; Yang S; He Z; Meng LY; Chen XG; Liu Y
    J Control Release; 2022 Nov; 351():255-271. PubMed ID: 36165836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boost Infiltration and Activity of T Cells via Inhibiting Ecto-5'-nucleotidase (CD73) Immune Checkpoint to Enhance Glioblastoma Immunotherapy.
    Zhang H; Yang L; Han M; Han Y; Jiang Z; Zheng Q; Dong J; Wang T; Li Z
    ACS Nano; 2024 Aug; 18(34):23001-23013. PubMed ID: 39150454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic nanodrug blocks CD73 to inhibit adenosine and boosts antitumor immune response synergically with photothermal stimulation.
    Li T; Zhang X; Shi C; Liu Q; Zhao Y
    J Nanobiotechnology; 2024 Apr; 22(1):214. PubMed ID: 38689291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis.
    Zou MZ; Liu WL; Li CX; Zheng DW; Zeng JY; Gao F; Ye JJ; Zhang XZ
    Small; 2018 Jul; 14(28):e1801120. PubMed ID: 29882235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
    Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
    Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models.
    Kaistha BP; Kar G; Dannhorn A; Watkins A; Opoku-Ansah G; Ilieva K; Mullins S; Anderton J; Galvani E; Garcon F; Lapointe JM; Brown L; Hair J; Slidel T; Luheshi N; Ryan K; Hardaker E; Dovedi S; Kumar R; Wilkinson RW; Hammond SA; Eyles J
    Cancer Biol Ther; 2024 Dec; 25(1):2296048. PubMed ID: 38206570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
    Lai X; Yao F; An Y; Li X; Yang XD
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-cell-biomimetic Upconversion nanoparticles combining chemo-photodynamic therapy and CD73 blockade for metastatic triple-negative breast cancer.
    Jin F; Qi J; Liu D; You Y; Shu G; Du Y; Wang J; Xu X; Ying X; Ji J; Du Y
    J Control Release; 2021 Sep; 337():90-104. PubMed ID: 34274385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
    Noman MZ; Desantis G; Janji B; Hasmim M; Karray S; Dessen P; Bronte V; Chouaib S
    J Exp Med; 2014 May; 211(5):781-90. PubMed ID: 24778419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.
    Zhao M; Yang X; Fu H; Chen C; Zhang Y; Wu Z; Duan Y; Sun Y
    ACS Appl Mater Interfaces; 2021 Jul; 13(28):32763-32779. PubMed ID: 34235912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allomelanin-based biomimetic nanotherapeutics for orthotopic glioblastoma targeted photothermal immunotherapy.
    Sun M; Li Y; Zhang W; Gu X; Wen R; Zhang K; Mao J; Huang C; Zhang X; Nie M; Zhang Z; Qi C; Cai K; Liu G
    Acta Biomater; 2023 Aug; 166():552-566. PubMed ID: 37236575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief.
    He M; Zhang M; Xu T; Xue S; Li D; Zhao Y; Zhi F; Ding D
    J Control Release; 2024 Apr; 368():233-250. PubMed ID: 38395154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
    Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
    Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation.
    Zhu L; Kuang X; Zhang G; Liang L; Liu D; Hu B; Xie Z; Li H; Liu H; Ye M; Chen X; Liu J
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
    Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
    Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.